DNA Repair Drugs: Global Markets
Report Scope:
This report provides an in-depth examination of the healthcare industry, with a particular emphasis on global market trend analysis. The report's goal is to provide an overview of the market for DNA repair drugs, as well as market segmentation by type, application and geography. During the forecast period, the market for DNA repair drugs is expected to grow rapidly. The report provides key statistics on the market status of the leading players in the DNA repair drug market, as well as key market trends and opportunities.
Report Includes:
This report provides an in-depth examination of the healthcare industry, with a particular emphasis on global market trend analysis. The report's goal is to provide an overview of the market for DNA repair drugs, as well as market segmentation by type, application and geography. During the forecast period, the market for DNA repair drugs is expected to grow rapidly. The report provides key statistics on the market status of the leading players in the DNA repair drug market, as well as key market trends and opportunities.
Report Includes:
- 20 data tables and 20 additional tables
- A brief general outlook of the global markets for DNA repair drugs within the biotech industry
- Analyses of the global market trends, with data from 2020 to 2021, and projections of compound annual growth rates (CAGRs) through 2026
- Discussion of major factors driving the growth of global DNA repair drugs market, industry structure, regulatory scenario and penetration of technologies within the marketplace
- Highlights of key market dynamics (DROs), current trends and emerging applications, federal regulations and opportunity assessment of next generation technologies anticipated to drive the progress of this market
- Evaluation of current market size and revenue forecast for DNA repair drugs in dollar value terms, and corresponding market share analysis by technology type, application and region
- Assessment of new developments relate to DNA research and type classification, their improvement techniques, focused scene investigation and patterns of advancements
- Insight into the R&D spendings in the pharmaceutical industry, approval of new drugs, projected revenues and cost analyses
- Emphasis on the SARS-CoV-2 Infection Impairs on DNA repair and inhibits
- Profile descriptions of the leading market players, including AbbVie, Bayer AG, Eli Lilly and Co., Johnson & Johnson, Novartis and Sanofi
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Market Estimates
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
DNA Damage
Sources of DNA Damage
DNA Repair Mechanism
Base Excision Repair and Nucleotide Excision Repair
Repair of Double-Strand Breaks
Nucleotide Excision Repair
Mismatch Repair
Homologous Recombination (HR)
Non-Homologous End Joining (NHEJ)
Alternative End Joining
Targets for Cancer Therapy
DNA Damage Response for Cancer Chemotherapy
Targeting PARP-1
Targeting APE
Targeting XRCC
Targeting DNA-PKcs
Targeting Ligases
Targeting PI-3 kinase
CHAPTER 4 MARKET BREAKDOWN BY TECHNOLOGY TYPE
Poly(ADP-Ribose) Polymerase Inhibitors
Structure and Function of PARP Inhibitors
Use of PARP Inhibitors in Treatment
FDA-approved PARP Inhibitors for Use in Cancer Treatment
PARP Inhibitors in Clinical Trials
CHAPTER 5 MARKET BREAKDOWN BY APPLICATION
Ovarian Cancer
Epidemiology of Ovarian Cancer
Risk Factors for Ovarian Cancer
Breast Cancer
Risk Factors for Breast Cancer
Signs and Symptoms
Treatment
Challenges
Global Impact
CHAPTER 6 MARKET BREAKDOWN BY REGION
Market Overview and Discussion
Rise of DNA Repair Cases by Region
North America
Europe
Asia-Pacific
Rest of the World
CHAPTER 7 R&D IN THE PHARMACEUTICAL INDUSTRY
Healthcare Expenditures
Continued Emphasis on R&D Activities
Trends in the Pharmaceutical Industry
Factors Influencing Spending for R&D
Trends in R&D Spending and New Drug Development
R&D Spending
New Drug Development
Approvals of New Drugs
Trends in Recent Drug Spending by Therapeutic Class
Types of New Drug Development
Factors Influencing R&D Spending
Projected Revenues
Revenues as Funding for R&D
New Drug Costs in R&D
CHAPTER 8 DNA REPAIR INHIBITORS ON SARS-COV-2
Biological Structure of SARS-CoV-2
Viral Infection Induces DNA Damage
Federal Funding for the Development of COVID-19 Vaccines
CHAPTER 9 COMPANY PROFILES
ABBVIE INC.
AMGEN INC.
ABBOTT LABORATORIES
ASTRAZENECA PLC
BAYER AG
BRISTOL-MYERS SQUIBB CO.
ELI LILLY
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
JOHNSON & JOHNSON
MERCK & CO., INC.
MERCK KGAA
NOVARTIS AG
PFIZER INC.
SANOFI S.A.
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Market Estimates
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
DNA Damage
Sources of DNA Damage
DNA Repair Mechanism
Base Excision Repair and Nucleotide Excision Repair
Repair of Double-Strand Breaks
Nucleotide Excision Repair
Mismatch Repair
Homologous Recombination (HR)
Non-Homologous End Joining (NHEJ)
Alternative End Joining
Targets for Cancer Therapy
DNA Damage Response for Cancer Chemotherapy
Targeting PARP-1
Targeting APE
Targeting XRCC
Targeting DNA-PKcs
Targeting Ligases
Targeting PI-3 kinase
CHAPTER 4 MARKET BREAKDOWN BY TECHNOLOGY TYPE
Poly(ADP-Ribose) Polymerase Inhibitors
Structure and Function of PARP Inhibitors
Use of PARP Inhibitors in Treatment
FDA-approved PARP Inhibitors for Use in Cancer Treatment
PARP Inhibitors in Clinical Trials
CHAPTER 5 MARKET BREAKDOWN BY APPLICATION
Ovarian Cancer
Epidemiology of Ovarian Cancer
Risk Factors for Ovarian Cancer
Breast Cancer
Risk Factors for Breast Cancer
Signs and Symptoms
Treatment
Challenges
Global Impact
CHAPTER 6 MARKET BREAKDOWN BY REGION
Market Overview and Discussion
Rise of DNA Repair Cases by Region
North America
Europe
Asia-Pacific
Rest of the World
CHAPTER 7 R&D IN THE PHARMACEUTICAL INDUSTRY
Healthcare Expenditures
Continued Emphasis on R&D Activities
Trends in the Pharmaceutical Industry
Factors Influencing Spending for R&D
Trends in R&D Spending and New Drug Development
R&D Spending
New Drug Development
Approvals of New Drugs
Trends in Recent Drug Spending by Therapeutic Class
Types of New Drug Development
Factors Influencing R&D Spending
Projected Revenues
Revenues as Funding for R&D
New Drug Costs in R&D
CHAPTER 8 DNA REPAIR INHIBITORS ON SARS-COV-2
Biological Structure of SARS-CoV-2
Viral Infection Induces DNA Damage
Federal Funding for the Development of COVID-19 Vaccines
CHAPTER 9 COMPANY PROFILES
ABBVIE INC.
AMGEN INC.
ABBOTT LABORATORIES
ASTRAZENECA PLC
BAYER AG
BRISTOL-MYERS SQUIBB CO.
ELI LILLY
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
JOHNSON & JOHNSON
MERCK & CO., INC.
MERCK KGAA
NOVARTIS AG
PFIZER INC.
SANOFI S.A.
LIST OF TABLES
Summary Table: Global Market for DNA Repair Drugs, by Type, Through 2026
Table 1: Global Market for DNA Repair Drugs, by Type, Through 2026
Table 2: FDA-Approved PARP Inhibitors
Table 3: Global Market for DNA Repair Drugs, by Application, Through 2026
Table 4: Global Market for DNA Repair Drugs, by Region, Through 2026
Table 5: North American Market for DNA Repair Drugs, by Country, Through 2026
Table 6: European Market for DNA Repair Drugs, by Country, Through 2026
Table 7: Asia-Pacific Market for DNA Repair Drugs, by Country, Through 2026
Table 8: Rest of the World Market for DNA Repair Drugs, Through 2026
Table 9: AbbVie: Oncology Pharmaceutical Revenue, 2018-2020
Table 10: AbbVie: Oncology Pharmaceutical Products Portfolio
Table 11: AbbVie: Marketed Products
Table 12: AbbVie: Key Developments, 2021
Table 13: Allergan PLC: Marketed Products
Table 14: Amgen: Oncology Pharmaceutical Products Portfolio
Table 15: AstraZeneca: Oncology Pharmaceutical Products Portfolio
Table 16: AstraZeneca: Oncology Pharmaceutical Revenue, 2018-2020
Table 17: Bayer AG: Marketed Products
Table 18: Bayer AG: Oncology Pharmaceutical Products Portfolio
Table 19: Bayer AG: Oncology Pharmaceutical Revenue, 2018-2020
Table 20: Bristol-Myers Squibb: Oncology Pharmaceutical Products Portfolio
Table 21: Bristol-Myers Squibb: Oncology Pharmaceutical Revenue, 2018-2020
Table 22: Eli Lilly and Co.: Marketed Products
Table 23: Eli Lilly and Co.: Oncology Pharmaceutical Products Portfolio
Table 24: Eli Lilly and Co.: Oncology Pharmaceutical Revenue, 2018-2020
Table 25: Roche: Oncology Pharmaceutical Products Portfolio
Table 26: Roche: Oncology Pharmaceutical Revenue, 2018-2020
Table 27: Johnson & Johnson: Oncology Pharmaceutical Products Portfolio
Table 28: Johnson & Johnson: Oncology Pharmaceutical Revenue, 2018-2020
Table 29: Merck & Co., Inc.: Marketed Products
Table 30: Merck & Co., Inc.: Oncology Pharmaceutical Products Portfolio
Table 31: Merck & Co., Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 32: Merck KGaA: Marketed Products
Table 33: Novartis: Oncology Pharmaceutical Products Portfolio
Table 34: Novartis: Oncology Pharmaceutical Revenue, 2018-2020
Table 35: Pfizer Inc.: Oncology Pharmaceutical Products Portfolio
Table 36: Pfizer Inc.: Marketed Products
Table 37: Pfizer Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 38: Sanofi: Oncology Pharmaceutical Products Portfolio
Table 39: Sanofi: Oncology Pharmaceutical Revenue, 2018-2020
Summary Table: Global Market for DNA Repair Drugs, by Type, Through 2026
Table 1: Global Market for DNA Repair Drugs, by Type, Through 2026
Table 2: FDA-Approved PARP Inhibitors
Table 3: Global Market for DNA Repair Drugs, by Application, Through 2026
Table 4: Global Market for DNA Repair Drugs, by Region, Through 2026
Table 5: North American Market for DNA Repair Drugs, by Country, Through 2026
Table 6: European Market for DNA Repair Drugs, by Country, Through 2026
Table 7: Asia-Pacific Market for DNA Repair Drugs, by Country, Through 2026
Table 8: Rest of the World Market for DNA Repair Drugs, Through 2026
Table 9: AbbVie: Oncology Pharmaceutical Revenue, 2018-2020
Table 10: AbbVie: Oncology Pharmaceutical Products Portfolio
Table 11: AbbVie: Marketed Products
Table 12: AbbVie: Key Developments, 2021
Table 13: Allergan PLC: Marketed Products
Table 14: Amgen: Oncology Pharmaceutical Products Portfolio
Table 15: AstraZeneca: Oncology Pharmaceutical Products Portfolio
Table 16: AstraZeneca: Oncology Pharmaceutical Revenue, 2018-2020
Table 17: Bayer AG: Marketed Products
Table 18: Bayer AG: Oncology Pharmaceutical Products Portfolio
Table 19: Bayer AG: Oncology Pharmaceutical Revenue, 2018-2020
Table 20: Bristol-Myers Squibb: Oncology Pharmaceutical Products Portfolio
Table 21: Bristol-Myers Squibb: Oncology Pharmaceutical Revenue, 2018-2020
Table 22: Eli Lilly and Co.: Marketed Products
Table 23: Eli Lilly and Co.: Oncology Pharmaceutical Products Portfolio
Table 24: Eli Lilly and Co.: Oncology Pharmaceutical Revenue, 2018-2020
Table 25: Roche: Oncology Pharmaceutical Products Portfolio
Table 26: Roche: Oncology Pharmaceutical Revenue, 2018-2020
Table 27: Johnson & Johnson: Oncology Pharmaceutical Products Portfolio
Table 28: Johnson & Johnson: Oncology Pharmaceutical Revenue, 2018-2020
Table 29: Merck & Co., Inc.: Marketed Products
Table 30: Merck & Co., Inc.: Oncology Pharmaceutical Products Portfolio
Table 31: Merck & Co., Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 32: Merck KGaA: Marketed Products
Table 33: Novartis: Oncology Pharmaceutical Products Portfolio
Table 34: Novartis: Oncology Pharmaceutical Revenue, 2018-2020
Table 35: Pfizer Inc.: Oncology Pharmaceutical Products Portfolio
Table 36: Pfizer Inc.: Marketed Products
Table 37: Pfizer Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 38: Sanofi: Oncology Pharmaceutical Products Portfolio
Table 39: Sanofi: Oncology Pharmaceutical Revenue, 2018-2020
LIST OF FIGURES
Summary Figure: Global Market for DNA Repair Drugs, by Type, 2020-2026
Figure 1: Pathway of Cellular DNA Damage and Repair
Figure 2: Chemical Structural of DNA Nucleotides
Figure 3: Direct Repair of Thymine Dimers
Figure 4: Repair of O6 - Methylguanine
Figure 5: Short-Patch and Long-Patch BER Pathways
Figure 6: Mechanism of NHEJ Repair of Double-Strand Breaks in DNA
Figure 7: Characteristics-Based Excision Repair, Nucleotide Excision Repair and Mismatch Repair
Figure 8: DNA Double Stand Base Repair Pathway
Figure 9: Environmental Gear Selection
Figure 10: Global Market for DNA Repair Drugs, by Type, 2020-2026
Figure 11: Structure Schematic of PARP Molecule
Figure 12: Interaction Between PARP and HR
Figure 13: Chemical Structure Formula of PARP Inhibitors
Figure 14: Global Market for DNA Repair Drugs, by Application, 2020-2026
Figure 15: Incidence, Mortality and Prevalence of Ovarian Cancer
Figure 16: Ovarian Cancer by Region and Gender
Figure 17: Incidence, Mortality and Prevalence of Breast Cancer
Figure 18: Breast Cancer, by Region and Gender
Figure 19: Global Market Shares for DNA Repair Drugs, by Region, 2020
Figure 20: North American Market Shares for DNA Repair Drugs, by Country, 2020
Figure 21: European Market Shares for DNA Repair Drugs, by Country, 2020
Figure 22: Asia-Pacific Market Shares for DNA Repair Drugs, by Country, 2020
Figure 23: R&D Intensities for Publicly Traded U.S. Companies
Figure 24: Annual Approvals of New Drugs by FDA
Figure 25: New Drug Approvals
Figure 26: U.S. Retail Drug Spending by Therapeutic Area
Figure 27: BARDA Funding for COVID-19 Vaccine
Summary Figure: Global Market for DNA Repair Drugs, by Type, 2020-2026
Figure 1: Pathway of Cellular DNA Damage and Repair
Figure 2: Chemical Structural of DNA Nucleotides
Figure 3: Direct Repair of Thymine Dimers
Figure 4: Repair of O6 - Methylguanine
Figure 5: Short-Patch and Long-Patch BER Pathways
Figure 6: Mechanism of NHEJ Repair of Double-Strand Breaks in DNA
Figure 7: Characteristics-Based Excision Repair, Nucleotide Excision Repair and Mismatch Repair
Figure 8: DNA Double Stand Base Repair Pathway
Figure 9: Environmental Gear Selection
Figure 10: Global Market for DNA Repair Drugs, by Type, 2020-2026
Figure 11: Structure Schematic of PARP Molecule
Figure 12: Interaction Between PARP and HR
Figure 13: Chemical Structure Formula of PARP Inhibitors
Figure 14: Global Market for DNA Repair Drugs, by Application, 2020-2026
Figure 15: Incidence, Mortality and Prevalence of Ovarian Cancer
Figure 16: Ovarian Cancer by Region and Gender
Figure 17: Incidence, Mortality and Prevalence of Breast Cancer
Figure 18: Breast Cancer, by Region and Gender
Figure 19: Global Market Shares for DNA Repair Drugs, by Region, 2020
Figure 20: North American Market Shares for DNA Repair Drugs, by Country, 2020
Figure 21: European Market Shares for DNA Repair Drugs, by Country, 2020
Figure 22: Asia-Pacific Market Shares for DNA Repair Drugs, by Country, 2020
Figure 23: R&D Intensities for Publicly Traded U.S. Companies
Figure 24: Annual Approvals of New Drugs by FDA
Figure 25: New Drug Approvals
Figure 26: U.S. Retail Drug Spending by Therapeutic Area
Figure 27: BARDA Funding for COVID-19 Vaccine
